Pharvaris (PHVS) reported Tuesday Q1 loss of 0.60 euros ($0.70) per diluted share, narrowing from a loss of 0.85 euros a year earlier.
Analysts polled by FactSet expected a loss of 0.71 euros.
Cash and cash equivalents were 247 million euros as of March 31. The company said a subsequent $132 million underwritten offering is expected to extend its cash runway into 2028.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.